Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): January 24, 2003

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

          Delaware                     000-14879                  222322400
(State or Other Jurisdiction    (Commission File Number)       (IRS Employer
      of Incorporation)                                      Identification No.)

650 College Road East, 3rd Floor, Princeton, NJ                         08540
(Address of Principal Executive Offices)                             (Zip Code)

                                 (609) 750-8200
                         (Registrant's telephone number,
                              including area code)

          (Former Name or Former Address, if Changed Since Last Report)

     Item 5.    Other Events and Required FD Disclosure.

Product Update and Conference Call

     On January 24, 2003,  Cytogen  Corporation  (the "Company")  issued a press
release   announcing  that  it  provided  DRAXIMAGE  Inc.   ("DRAXIMAGE"),   the
radiopharmaceutical subsidiary of DRAXIS Health Inc., with notice of termination
of each of its License and Distribution  Agreement and Product Manufacturing and
Supply  Agreement  with  respect  to both of  DRAXIS'  BrachySeed(TM)  I-125 and
BrachySeed(TM) PD-103 products. Cytogen provided such notice of termination upon
a  determination  that  there  is no  reasonable  expectation  that  DRAXIS  can
consistently supply the BrachySeed products at quantities,  activity levels, and
schedules  amendable to commercial sale, which has negatively impacted Cytogen's
ability to market  such  products.  Such press  release  is  attached  hereto as
Exhibit 99.1 and is incorporated herein by reference.

     On January 27, 2003, the Company issued a press release  announcing that it
will be hosting a conference call today, Monday, January 27, 2003, at 11:00 a.m.
Eastern  Time  regarding  this  matter.   To  participate  in  the  call,   dial
877-356-8058  or  706-643-7672.  This  call is  also  being  webcast  and can be
accessed through the Company's website at by selecting Investor
Relations.  A replay of the conference call will be available on the website for
two weeks  following  the call and an audio replay will be  available  after the
conference  call and lasting  until  midnight,  February  25,  2003,  by calling
800-642-1687 or 706-645-9291 and entering the conference ID number 7914576. Such
press release is attached hereto as Exhibit 99.2 and is  incorporated  herein by

     A copy of the script with respect to the conference call is attached hereto
as  Exhibit  99.3  and  is  incorporated  herein  by  reference.  The  foregoing
descriptions of such press releases are qualified in their entirety by reference
to each such document.

     Item 7.   Financial Statements, Pro Forma Financial Information and

     (c)   Exhibits.

            Exhibit No.      Description
            -----------      -----------

               99.1          Press release of the Company dated January 24, 2003

               99.2          Press release of the Company dated January 27, 2003

               99.3          Script of conference call to be held on January 27,


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Cytogen Corporation

                                      By:  /s/ Michael D. Becker
                                           Michael D. Becker
                                           President and Chief Executive Officer

Date:  January 27, 2003